Tgtx stock price forecast?
TGTX Stock 12 Months Forecast
Should I buy TGTX?
Tg Therapeutics Stock Forecast FAQ
Is Tg Therapeutics Stock a good buy in 2024, according to Wall Street analysts? The consensus among 4 Wall Street analysts covering (NASDAQ: TGTX) stock is to Strong Buy TGTX stock.
What is the TGTX forecast for 2024?
According to our current TGTX stock forecast, the value of TG Therapeutics shares will rise by 1.72% and reach $ 16.07 per share by February 1, 2024. According to our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).
What is the CNN forecast for TGTX?
TG Therapeutics Inc (NASDAQ:TGTX)
The 8 analysts offering 12-month price forecasts for TG Therapeutics Inc have a median target of 30.75, with a high estimate of 45.00 and a low estimate of 7.00.
What is the earnings forecast for TGTX?
Earnings announcement* for TGTX: Feb 27, 2024
Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.11.
Will TGTX get FDA approval?
TGTX announced that the FDA has approved its anti-CD20 monoclonal antibody, Briumvi (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Why is TGTX going down?
Sales of a new multiple sclerosis drug from TG Therapeutics (TGTX) crushed analysts' expectations, but TGTX stock tumbled on lackluster 2024 guidance. For the year, the biotech company expects $220 million to $260 million in sales of Briumvi, its new treatment for relapsing forms of multiple sclerosis.
Who owns TGTX stock?
Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, XBI - SPDR(R) S&P(R) Biotech ETF, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Paradigm Biocapital Advisors LP, NAESX - Vanguard Small-Cap Index Fund Investor Shares, IWM - iShares Russell 2000 ETF, Wellington ...
Does TGTX pay a dividend?
Tg Therapeutics (NASDAQ: TGTX) does not pay a dividend.
What is the target stock price forecast for 2024?
Target Stock Price Forecast 2024-2025
Target price started in 2024 at $142.42. Today, Target traded at $142.53, so the price decreased by 0% from the beginning of the year. The forecasted Target price at the end of 2024 is $187 - and the year to year change +31%. The rise from today to year-end: +31%.
What is the stock price forecast for Regeneron in 2030?
Regeneron Pharmaceuticals Stock Prediction 2030
In 2030, the Regeneron Pharmaceuticals stock will reach $ 2,017.13 if it maintains its current 10-year average growth rate. If this Regeneron Pharmaceuticals stock prediction for 2030 materializes, REGN stock willgrow 112.58% from its current price.
What is the future stock price of GFS?
Stock Price Forecast
The 14 analysts with 12-month price forecasts for GlobalFoundries stock have an average target of 71.43, with a low estimate of 65 and a high estimate of 80. The average target predicts an increase of 26.42% from the current stock price of 56.50.
Is Outlook Therapeutics a buy?
Outlook Therapeutics's analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
What is the target price for FGEN stock?
Stock Price Forecast
The 1 analysts offering 12-month price forecasts for FibroGen Inc have a median target of 0.50, with a high estimate of 0.50 and a low estimate of 0.50. The median estimate represents a -35.82% decrease from the last price of 0.78.
What is the target price for Nutex Health stock?
What are analysts forecasts for Nutex Health stock? The 6 analysts offering price forecasts for Nutex Health have a median target of 2.25, with a high estimate of 3.00 and a low estimate of 1.00. The median estimate represents a 5.95 difference from the last price of 0.13.
What is the stock price prediction for Nutex Health?
The Wall Street analyst predicted that Nutex Health's share price could reach $1.50 by Nov 14, 2024. The average Nutex Health stock price prediction forecasts a potential upside of 624.64% from the current NUTX share price of $0.21. (NASDAQ: NUTX) forecast ROE is N/A, which is considered weak.
What is the new FDA approved MS drug?
FDA Approves Natalizumab Biosimilar, First for Multiple Sclerosis.
Who is the manufacturer of Briumvi?
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.
How much does Briumvi cost a year?
Recently, TG Therapeutics announced that it plans to make Briumvi the most accessible therapy in its class by pricing it at $59,000 per year.
Who are Tgtx competitors?
The main competitors of TG Therapeutics include Xenon Pharmaceuticals (XENE), Bausch Health Companies (BHC), Prestige Consumer Healthcare (PBH), Evotec (EVO), HUTCHMED (HCM), Gemini Therapeutics (GMTX), CymaBay Therapeutics (CBAY), Galapagos (GLPG), Amphastar Pharmaceuticals (AMPH), and MoonLake Immunotherapeutics ( ...
Who is the CEO of Tgtx?
Michael S. Weiss founded and has served as the Company's Chairman, President and CEO since December 2011.
What does TG Therapeutics do?
Related keylists. TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and various autoimmune diseases.
Is Denali Therapeutics public?
Denali Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 10,377,359 shares of its common stock at a price to the public of $26.50 per share.
What is the stock symbol for Global Blood Therapeutics?
Global Blood Therapeutics (GBT) Stock Forecast, Price Targets and Analysts Predictions - TipRanks.com.
How often does Eaton pay dividends?
Eaton Corporation plc ( ETN ) pays dividends on a quarterly basis. Eaton Corporation plc ( ETN ) has increased its dividends for 15 consecutive years. This is a positive sign of the company's financial stability and its ability to pay consistent dividends in the future.
